4.4 Article

The Rakicidin Family of Anticancer Natural Products - Synthetic Strategies towards a New Class of Hypoxia-Selective Cytotoxins

Journal

SYNLETT
Volume 27, Issue 13, Pages 1898-1906

Publisher

GEORG THIEME VERLAG KG
DOI: 10.1055/s-0035-1561465

Keywords

total synthesis; cyclic peptide; cancer; tumor hypoxia; natural products

Funding

  1. Lundbeck foundation
  2. Danish Cancer Society
  3. Carlsberg foundation
  4. Ministry of Higher Education and Science [AU-2010-612-181]
  5. Lundbeck Foundation [R105-2011-9308] Funding Source: researchfish

Ask authors/readers for more resources

Rakicidin A is a prominent member of a small class of macrocyclic lipodepsipeptide natural products that contain an electrophilic 4-amido-2,4-pentadienoate (APD) functionality. Rakicidin A displays selective growth inhibitory activity against hypoxic cancer cells as well as imatinib-resistant chronic myelogenous leukemia (CML) cells. In this paper we present and discuss the two known synthetic routes to rakicidin A, which provide an instructive comparison of strategies used to address the synthetic challenges inherent to rakicidin A. In addition to the synthetic discussion we provide a status on the ongoing biological investigations and emerging structure-activity relationships of the rakicidin scaffold. 1 Introduction 2 The APD-CLD Class of Natural Products 3 Total Syntheses of Rakicidin A 4 Biological Investigations of Rakicidin A and Analogues 5 Conclusion and Perspectives

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available